clock menu more-arrow no yes

Filed under:


Gull Laboratories Inc. reports first quarter revenues of $4.89 million, down slightly from $4.91 million for the same period last year.

Operating income of $522,579 was up 20.5 percent over the first quarter of 1995.Net income was $225,940 or 3 cents per share for the quarter compared to $373,603 or 6 cents per share for the same period the previous year.

Meanwhile Tuesday, the Salt Lake-based medical products manufacturer, said it has hired the New York firm Corporate Investors Network as its counsel for investor relations.

Under a contract effective Tuesday, Corporate Investors will assist Gull in creating a new financial communications program.

"We know that we need to do more than rely on news releases and annual reports to distribute information and attract potential investors," said George Evanega, Gull's chief executive officer.

He said Corporate Investors has the "credibility, influence and expertise to raise Gull's visibility in the investment community and to build the quality of Gull's share-holders."

Gull manufactures diagnostic test kits and automated systems.